



Standard Medical & Pharmaceuticals Limited

C.A.M.

Standard Medical & Pharmaceuticals Limited, 100, Phiroze Jeejeebhoy Street, MUMBAI - 400 002

Dept. The B
1st Flc
Dalal

Dear Sir,

of Corporate Serv
ombay Stock Excl
or, Phiroze Jeejee
Street, MUMBAI

We
14.02

Sub: Outcome
Disclosur
Disclosur

1w

Unit: Standard

ould like to in
2018, has inter-

We
mon

Considered and
Quarter and ni

The l

he Audit Comr
of the Statutory /

This

are
the herewith encl

Thar

Bo period ended D

Your
for S

isard meeting con
for S

ankfor your kind in

Srini

ing You,

Manta

DIN

faithfully,
(ndard Medical &

iva

ag

asa Raju Godavar

ing Director

01677606

R



INTERIM FINANCIAL STATEMENT REVIEW REPORT

To,
**The Board of Directors,
Standard Medical & Pharmaceuticals Limited**

We have reviewed the accompanying **Interim Financial Statement** of **Standard Medical & Pharmaceuticals Limited** submitted by the company pursuant to the requirements of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Interim Financial Reporting) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in Indian Accounting Standard as prescribed under the companies Act, 2013 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the management and has been expressed in the statement to express a conclusion on the statement.

We conducted our review in accordance with the Standard on Review Engagement (SRE) issued by the Chartered Accountants of India. This standard requires that we plan and perform the review to provide moderate assurance as to whether the financial statements are free of material misstatements. This provides less assurance than an audit and we have not performed an audit.

Based on our review conducted above, nothing has come to our attention which causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles issued by the Institute of Chartered Accountants of India ("Ind AS") specified under the Companies Act, 2013 and other recognized accounting practices, has not disclosed the information required to be disclosed in terms of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Interim Financial Reporting) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, in the manner in which the information is to be disclosed.

Place: Hyderabad
Date: 14th February, 2018

I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
XIII
XIV
XV
XVI
XVII
XVIII
XVII
I

Note

- 1
- 2
- 3
- 4

